How Should We Deal with Patient Heterogeneity in Economic Evaluation: A Systematic Review of National Pharmacoeconomic Guidelines  by Ramaekers, Bram L.T. et al.
Avai lable onl ine at www.sc iencedirect .comVA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 8 5 5 – 8 6 21098-3015/$36.00 –
Published by Elsevie
http://dx.doi.org/10
This article was
Technology Assessm
18–21, 2012, Zu¨rich)
E-mail: bram.ram
 Address correspjournal homepage: www.elsevier .com/ locate / jva lSYSTEMATIC REVIEWSHow Should We Deal with Patient Heterogeneity in Economic Evaluation:
A Systematic Review of National Pharmacoeconomic Guidelines
Bram L.T. Ramaekers, MSc1,2,, Manuela A. Joore, PhD2, Janneke P.C. Grutters, PhD3
1Department of Health Services Research, Maastricht University, Maastricht, The Netherlands; 2Department of Clinical Epidemiology and Medical Technology
Assessment, Maastricht University Medical Center. Maastricht, The Netherlands; 3Department for Health Evidence & Operating Rooms, University Medical
Center, St. Radboud, Nijmegen, The Netherlands
A B S T R A C TObjective: To review and analyze recommendations from national
pharmacoeconomic guidelines with regard to acknowledging patient
heterogeneity in economic evaluations. Methods: National pharma-
coeconomic guidelines were obtained through the ISPOR Web site.
Guidance was extracted by using a developed data extraction sheet.
Extracted data were divided into subcategories on the basis of
consensus meetings. Results: Of the 26 included guidelines, 20
(77%) advised to identify patient heterogeneity. Most guidelines
(77%) provided general methodological advice to acknowledge patient
heterogeneity, including justifications for distinguishing subgroups
(65%), prespecification of subgroups (42%), or methodology to
acknowledge patient heterogeneity (77%). Stratified analysis of cost-
effectiveness was most commonly advised (20 guidelines; 77%);
however, guidance on the specific application of methods was scarce
(9 guidelines; 34%) and generally limited if provided. Guidance to
present patient heterogeneity was provided by 15 guidelines (58%),
most prominently to describe the definition (31%) and justification
(31%) of subgroups. Conclusions: The majority of nationalsee front matter Copyright & 2013, International
r Inc.
.1016/j.jval.2013.02.013
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ondence to: Bram L.T. Ramaekers, P.O. Box 5800, 62pharmacoeconomic guidelines provide guidance on acknowledging
patient heterogeneity in economic evaluations. However, because
guidance is mostly not specific, its usefulness is limited. This may
reflect that the importance of acknowledging patient heterogeneity
is usually recognized while there is a lack of consensus on specific
methods to acknowledge patient heterogeneity. We advise the
further development of national pharmacoeconomic guidelines to
provide specific guidance on the identification of patient hetero-
geneity, methods to acknowledge it, and presenting the results. We
present a checklist that can assist in formulating these recom-
mendations. This could facilitate the systematic and transparent
handling of patient heterogeneity in economic evaluations
worldwide.
Keywords: economic evaluation, national pharmacoeconomic
guideline, patient heterogeneity, systematic review.
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Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Considering the rapidly increasing health care costs and the
finite amount of available resources, the criteria to grant reim-
bursement to new treatments have become more restricted.
These reimbursement decisions are often made for groups of
patients. A more individualized approach for the allocation of
available resources, that is, providing treatment reimbursement
for subgroups of patients, however, has the potential to increase
population health gains [1–4]. Acknowledging patient heteroge-
neity in reimbursement decisions may lead to more efficient
health care if these reimbursement decisions are based on cost-
effectiveness [5]. As economic evaluations are frequently used to
estimate cost-effectiveness and support reimbursement decision
making [6], it is essential that patient heterogeneity be incorpo-
rated in economic evaluations. Although there is consensus onits importance [7], patient heterogeneity is frequently neglected
in economic evaluations [8].
Patient heterogeneity might be neglected because subgroup
policy sometimes is controversial due to ethical concerns. This
may lead to equity constraints, where the use of certain
characteristics is considered unacceptable to determine which
subgroups have access to a technology. The acknowledgment of
patient heterogeneity in economic evaluations also seems to be
hampered by a lack of clarity on when and how this should be
done [2,9]. In this respect, there is an important role for national
pharmacoeconomic guidelines. National pharmacoeconomic
guidelines provide essential guidance how economic evalua-
tions, with the purpose to support reimbursements decision
making, should be performed within a jurisdiction. The objec-
tive of this study was therefore to review and analyze recom-
mendations from national pharmacoeconomic guidelines withSociety for Pharmacoeconomics and Outcomes Research (ISPOR).
onomists’ Study Group (May 24–25, 2012, Almen), at the Health
ilbao), and at the European Conference on Health Economics (July
02 AZ Maastricht, The Netherlands.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 8 5 5 – 8 6 2856regard to acknowledging patient heterogeneity in economic
evaluations.Methods
Definition of Patient Heterogeneity
Patient heterogeneity was defined as the part of the natural
variation between patients (variability) that can be attributed to
characteristics of those patients [6,9,10]. This was differentiated
from treatment variability (differences in the nature of the
treatment), differences between geographical regions that may
impact cost-effectiveness, and statistical heterogeneity. These
concepts relate more to the generalizability of cost-effectiveness
results [9,11] and variation in outcomes between studies (e.g.,
included in a meta-analysis) and are beyond the scope of this
review.
Characteristics that potentially explain patient heterogeneity
include demographics (e.g., age, sex, and income), preferences
(e.g., attitude, beliefs, and risk tolerance), and/or clinical charac-
teristics (e.g., disease severity, disease history, and genetic profile)
[9]. These sources of patient heterogeneity may have an impact
on different input parameters used in an economic evaluation:
baseline risks, relative treatment effects, health state utility, and
resource utilization [9]. Differences in unit costs are more likely a
result of differences between geographical regions and are thus
not considered in this review [9,12].
Search Strategy and Data Extraction
Consistent with previous reviews of national pharmacoeconomic
guidelines [12,13], national pharmacoeconomic guidelines were
obtained through the link provided on the International Society
for Pharmacoeconomics and Outcomes Research (ISPOR) Web
site (www.ispor.org) [14] and retrieved from the Web site of the
guideline agencies. This was done to ensure that the most recent
versions were retrieved. The ISPOR Web site was considered a
reliable and valid source because the overview of national
pharmacoeconomic guidelines is based on contacts with experts
from approximately 60 countries from around the world [12].
Guidelines were included if they were available in English. To
systematically extract relevant guidance, we used a data extract-
ion sheet (see Appendix 1 in Supplemental Materials found at
http://dx.doi.org/10.1016/j.jval.2013.02.013) containing the follow-
ing categories:1. Acknowledgment of patient heterogeneity: whether guide-
lines advised to identify patient heterogeneity and whether
a distinction is made between different inputs of an economic
evaluation: 1) baseline risk, 2) relative treatment effect, 3)
health state utility, and 4) resource utilization.2. Methodology to acknowledge patient heterogeneity: whether
guidelines advised methodology to acknowledge patient het-
erogeneity. This contains guidance whether to justify for
acknowledging patient heterogeneity (including equity con-
straints), guidance whether to a priori prespecify potential
sources of patient heterogeneity, general methods, and the
specific application of methods to acknowledge patient
heterogeneity.3. Presentation of patient heterogeneity: whether guidelines
advised what should be presented when acknowledging
patient heterogeneity.
Data were extracted and categorized (into the above-
mentioned categories) by one author (B.R.). Extracted data from
all guidelines were divided into subcategories. If the classification
of guidance was ambiguous, it was independently judged by theother authors (J.G. and M.J.). Possible discrepancies were dis-
cussed to reach consensus.Results
In total 33 guidelines were retrieved. Seven guidelines were
excluded because they were not available in English [15–21]. This
accumulated to 26 included guidelines, published between 1997
and 2012 [22–47].
Acknowledgment of Patient Heterogeneity
Most guidelines (20; 77%) advise to identify patient heterogeneity
in general [22–41]. Thirteen guidelines (50%) explicitly consider it
relevant to identify the impact of patient heterogeneity on effects
in general (irrespective of whether it has an impact on the
baseline risk and/or treatment effect) [22–25,27,29,30,32,
34–36,38,40]. Seven guidelines (27%) specify this into differences
in baseline risk and treatment effect and consider them both as
relevant [22–25,30,32,36]. In addition, four guidelines consider it
relevant to reflect the impact of patient heterogeneity on health
state utility [24,27,30,34]. Nine guidelines (35%) consider differ-
ences in resource utilization as relevant input to acknowledge
patient heterogeneity [23–25,29,30,34,36,38,40]. None of the guide-
lines advise not to identify patient heterogeneity in any of these
four key inputs of an economic evaluation.
Methodology to Acknowledge Patient Heterogeneity in
Economic Evaluations
Methodological guidance on acknowledging patient heterogene-
ity is provided by 20 guidelines (77%) [22–41].
Arguments to justify acknowledging patient heterogeneity in
economic evaluations
Arguments to justify acknowledging patient heterogeneity are
required by 17 guidelines (65%) [22–27,29,30,32–37,39–41]. Only the
England & Wales guideline [25] lists equity constraints (Table 1).
Instead of neglecting subgroups based on a particular equity point
of view, the Canadian guideline [24] proposes to calculate the
opportunity costs of equity concerns by using the framework
proposed by Coyle et al. [1]. These opportunity costs can be
interpreted as the costs of neglecting subgroups based on grounds
of equity. Hence, this framework aims to inform the trade-off
between equity and efficiency [1]. In addition, the German guide-
line states that only those subgroups should be addressed for
which an additional benefit or lesser harm was established [28].
Specification of potential sources of patient heterogeneity
Eight guidelines (31%) [22,24,25,29,30,32,35,37] advise to prespe-
cify potential sources of patient heterogeneity (Table 1). The
French guideline considers post hoc multivariate analysis accept-
able to explore patient heterogeneity [27]. Post hoc analysis is
allowed under certain conditions by eight guidelines (31%): only
for differences in costs [23], with (strong) justification [24,36] and/
or if interpreted as explorative [23], with caution [22,30,32], or
hypothesis generating [24,35].
How to acknowledge patient heterogeneity
Most guidelines (20; 77%) provide general advice how to acknowl-
edge patient heterogeneity [22–41]. Stratified analysis is the most
commonly advised method [22–41]. The French, German, and
Scottish guidelines generally advise the use of decision analytic
modeling [27,28,36]. Furthermore, sensitivity and/or scenario
analyses are advised by the guidelines from Australia, Canada,
and England & Wales [22,24,25]. Although most guidelines
Table 1 – Overview of advice on methodology from guidelines (N ¼ 26) to acknowledge patient heterogeneity.
Guidelines, n (%) Countries
Total 20 (77) AU, BC, BE, CA, EW, FI, FR, DE, HU, IE, IT, NZ, NO, PL, PT,
SL, ZA, ES, SE, US
A Guidelines that advised to justify for acknowledging
patient heterogeneity
17 (65) AU, BC, BE, CA, EW, FI, FR, HU, IE, NZ, NO, PL, PT, SL,
ZA, SE, US
Specific guidance:
 If plausible based on (pre)clinical evidence/
pharmacokinetics
11 (42) AU, BC, BE, EW, FR, HU, IE, NZ, PT, ZA, US
 If plausible based on a priori expectations of cost-
effectiveness
7 (27) BC, BE, EW, HU, IE, SE, US
 If biologically plausible 5 (19) AU, EW, IE, NZ, SL
 If statistically plausible 4 (15) AU, FR, NZ, ZA
 If patients for whom it is most (cost-)
effective can be targeted/if relevant for decision
4 (15) NZ, NO, ZA, US
 If relevant for distributive aspects/if patient groups
likely to be disadvantaged can be targeted
2 (8) CA, FR
 If informative for value-based pricing 1 (4) FI
 If subgroups are within the approved indication 1 (4) ZA
 If not solely based on: 1) individual utilities for
health states and patient preferences, or 2)
differential treatment costs for individuals according
to their social characteristics
1 (4) EW
B Guidelines that advised to prespecify potential
sources of patient heterogeneity
11 (42) AU, BE, CA, EW, FR, HU, IE, NZ, PT, SL, ZA
Specific guidance:
 Prespecify subgroups 8 (31) AU, CA, EW, HU, IE, NZ, PT, ZA
 Interpret post hoc analysis as explorative/as
hypothesis generating/with caution
6 (23) AU, BE, CA, IE, NZ, PT
 Ad hoc data mining should be avoided 3 (12) BE, EW, SL
 Post hoc analysis is allowed only with (strong)
justification
2 (8) CA, SL
 Post hoc analysis only for differences in costs 1 (4) BE
 Post hoc multivariate analysis is acceptable to
explore patient heterogeneity
1 (4) FR
C Guidelines that advised how to acknowledge patient
heterogeneity in economic evaluations
20 (77) AU, BC, BE, CA, EW, FI, FR, DE, HU, IE, IT, NZ, NO, PL, PT,
SL, ZA, ES, SE, US
Suggested methods:
 Stratified analysis 20 (77) AU, BC, BE, CA, EW, FI, FR, DE, HU, IE, IT, NZ, NO, PL, PT,
SL, ZA, ES, SE, US
 Decision analytic modeling 3 (12) FR, DE, SL
 Sensitivity analysis/scenario analysis 3 (12) AU, CA, EW
Specific advice on the application of methods:
 Statistical precision of subgroups estimates should
be reflected in the analysis of parameter uncertainty
3 (12) CA, EW, SL
 Calculate the impact of variability in baseline risk
by multiplying the expected baseline risk across
patient subgroups by the overall relative treatment
effect (established in the whole population)
3 (12) AU, BE, NZ
 Meta-regression to determine whether a treatment
effect varies across patient groups
2 (8) AU, SL
 Calculate the impact of variability in absolute
treatment effect by applying the estimated relative
treatment effect for the subgroups to the expected
baseline risk for the subgroups
1 (4) AU
 Discrete event simulation 1 (4) DE
 Sensitivity analysis for equity concerns and
subgroup thresholds
1 (4) AU
 Scenario analysis for treatment continuation rules 1 (4) EW
 Multivariate analysis to evaluate treatment
effectiveness depending on patient characteristics
1 (4) FR
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Table 1 – continued
Guidelines, n (%) Countries
 Separate models for separate subgroups 1 (4) CA
 Equivalent data for stratified analysis as for the
whole group
1 (4) FI
 Examine whether the relative risk is constant over
different baseline risk
1 (4) SL
 Explore the possibility that differences between
groups emerge by chance
1 (4) EW
Note. Country codes according to the ISO 3166-1 Alpha-2 if applicable: Australia [22], AU; Baltics (Latvia, Estonia, and Lithuania) [40], BC;
Belgium [23], BE; Canada [24], CA; England & Wales [25], EW; Finland [26], FI; France [27], FR; Germany [28], DE; Hungary [29], HU; Ireland [30];
IE; Israel [31], IL; New Zealand [32], NZ; Norway [33], NO; Poland [34], PL; Portugal [35], PT; Scotland [36], SL; South Africa [37], ZA; Spain [38], ES;
Sweden [39], SE; United States [41], US.
Unofficial codes.
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methods are provided by a minority (35%) of guidelines (Table 1)
[22–28,32,36].
The German guideline advises a specific form of modeling:
discrete event simulation. They argue that patient heterogeneity
can be incorporated into discrete event simulation as each
patient can be modeled with its unique characteristics [28]. The
Canadian guideline advises stratified cost-effectiveness analysis
according to the framework by Coyle et al. [1] to calculate the
potential efficiency gain of subgroup policy. The Australian
guideline argues that meta-regression is preferred above strati-
fied analysis because it allows to examine multiple covariates
simultaneously [22]. The French guideline advises the use of
multivariate analysis to evaluate treatment effectiveness
depending on patient characteristics [27]. In addition, the Aus-
tralian guideline advises that the absolute treatment effect can
be calculated in case of differences in baseline risk and/or
treatment effect by applying the estimated relative treatment
effect for the subgroups to the expected baseline risk for the
subgroups [22]. The Belgium and New Zealand guidelines advise
to multiply the expected baseline risk across patient subgroups
by the overall relative treatment effect (assuming a constant
relative treatment effect for all subgroups) [23,32].
The Australian guideline recommends performing sensitivity
analysis for equity concerns that affect the cost-effectiveness
and subgroup thresholds for continuous variables such as age
[22]. In addition, the England & Wales guideline advises scenario
analysis for treatment continuation rules [25]. These rules can be
used to adjust treatment plans based on patient heterogeneity
that is revealed over time (e.g., differences in treatment
response). The guideline provides guidance on the specification
of treatment continuation rules focusing on the feasibility,
robustness, and equity of implementing these rules [25]. Finally,
the England & Wales guideline advises to explore the possibility
that differences between subgroup emerge by chance, especially
in case numerous subgroups are reported [25].
Presenting Patient Heterogeneity
Guidance on presenting patient heterogeneity is provided by 15
guidelines (58%) [22–25,27,28,30,32,34,36–41] (Table 2). For the
‘‘Methods’’ section, the most common advice was to describe the
definition [22–25,28,32,36,37] and justification of subgroups
[22,23,25,30,32,34,36,40]. Cost-effectiveness estimates should be
presented separately for each subgroup in the ‘‘Results’’ section
according to seven guidelines (27%) [24,25,27,28,30,38,41]. Present-
ing the implications of subgroup policy on distributional aspects is
recommended by six guidelines (23%) [22,24,27,28,30,41]. Thisincludes highlighting unmet needs of certain disadvantaged
groups. The United States guideline advises to weigh subgroup
outcomes against moral values [41]. Detailed tables to present the
assessment of treatment effects across subgroups are provided by
the Australian guideline [22].
For the ‘‘Discussion’’ section, it was recommended to highlight
biomarkers/diagnostic tests necessary to identify relevant sub-
groups [22,41], whether subgroup results lead to different con-
clusions than the overall trial results [22], the credibility of the
claim to use subgroups [22,41], and the appropriate use of the
intervention [24].Discussion
We reviewed guidance from national pharmacoeconomic guide-
lines with regard to acknowledging patient heterogeneity in
economic evaluations. Although the majority of guidelines con-
sidered it relevant to acknowledge patient heterogeneity, only
few specified specifically which inputs of an economic evaluation
are relevant for this purpose. Consistently, most guidelines
provide general guidance how to acknowledge patient hetero-
geneity (mostly stratified analysis). Specific and in-depth guid-
ance on applying, for instance, stratified analysis or other
methods, however, was scarce and generally limited if provided.
Also, guidance was ‘‘heterogeneous’’ between guidelines. This
might reflect differences between health care systems or juris-
dictions. For example, if cost-effectiveness is important for
reimbursement decisions, guidelines might be more specific
and directive. This can be illustrated by England and Wales, in
which reimbursement decisions are based on cost-effectiveness
outcomes, and who accordingly provide one of the most specific
guidelines. Overall, our review revealed that the importance of
acknowledging patient heterogeneity is usually recognized, while
there is a lack of consensus and specific guidance on acknowl-
edging and presenting patient heterogeneity.
One study limitation was that we excluded seven guidelines
that were not written in English. Translations of guidelines from
South America and Asia would be helpful to obtain a complete
overview. Nevertheless, with 26 included guidelines, this review
provides a comprehensive and probably representative overview
of guidance on handling patient heterogeneity in economic
evaluation. Also, the review was restricted to guidelines avail-
able on the ISPOR Web site. As a result, some guidelines might
not be included in the review. However, when considering that a
large part of the national pharmacoeconomic guidelines is
published in the ‘‘gray literature,’’ a systematic search strategy
in, for instance, PubMed would most likely not lead to a
Table 2 – Overview of advice on the presentation of patient heterogeneity from guidelines (N ¼ 26).
Guidelines, n (%) Countries
Total 15 (58) AU, BC, BE, CA, EW, FR, DE, IE, NZ, PL, SL, ZA, ES, SE,
US
A Present in the ‘‘Objective/Methods’’ section: 12 (46) AU, BC, BE, CA, EW, DE, IE, NZ, PL, SL, ZA, SE
 Definition of subgroups 8 (31) AU, BE, CA, EW, DE, NZ, SL, ZA
 Justification for subgroups (prespecification or
biological/clinical/statistical reasoning)
8 (31) AU, BC, BE, EW, IE, NZ, PL, SL
 Epidemiological data/number of persons for the
subgroups
2 (8) BE, SE
 How stratified analysis was undertaken,
including the choice of scale on which any effect
modification is defined
2 (8) EW, SL
 Adjustments for multiple comparisons if
subgroups were non-presepcified
1 (4) AU
 Details of the statistical tests used 1 (4) SL
 Expected differences between subgroups in
methods
1 (4) BE
 Used methods to identify the baseline data for
stratified analysis
1 (4) EW
B Present in the ‘‘Results’’ section: 9 (35) AU, CA, EW, FR, DE, IE, PL, ES, US
 Cost-effectiveness information separately for
each subgroup
7 (27) CA, EW, FR, DE, IE, ES, US
 Implications for distributive aspects/equity 6 (23) AU, CA, FR, DE, IE, US
 The impact of using the intervention for
subgroups/how much the intervention is more
cost-effective in the subgroups
2 (8) DE, PL
 Subgroup results in a tornado diagram 2 (8) CA, IE
 Cost-effectiveness acceptability curves/efficiency
frontiers separately for each subgroup
1 (4) IE
 The number of prespecified and non-prespecified
stratified analysis
1 (4) AU
 The subgroups ‘‘n (event)/N’’ per trial, overall trial
results, treatment effect for subgroups, analysis
as relative risk and risk difference both per trial
and pooled
1 (4) AU
C Present in the ‘‘Discussion’’ section: 3 (12) AU, CA, US
 Discuss the claim to justify the use of subgroups
(e.g., evidence or pharmacological, biological,
and clinical plausibility for the variation in (cost-)
effectiveness)
2 (8) AU, US
 Discuss the biomarkers or other diagnostics (e.g.,
validity, reliability, and feasibility for clinical
practice) necessary to identify patient subgroups
2 (8) AU, US
 Discuss whether subgroup results lead to
different conclusions than the primary overall
trial results
1 (4) AU
 Discuss the appropriate use of the intervention 1 (4) CA
Note. Country codes according to the ISO 3166-1 Alpha-2 if applicable: Australia [21], AU; Baltics (Latvia, Estonia, and Lithuania) [20], BC;
Belgium [22], BE; Canada [23], CA; England & Wales [24], EW; France [37], FR; Germany [26], DE; Ireland [27], IE; New Zealand [29], NZ; Poland
[31], PL; Scotland [33], SL; South Africa [34], ZA; Spain [39], ES; Sweden [35], SE; United States [36], US.
Unofficial codes.
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tively, using personal knowledge and contacts to identify
national pharmacoeconomic guidelines would potentially lead
to selection bias; that is, pharmacoeconomic guidelines from
well-known guideline authorities (e.g., the National Institute for
Health and Clinical Excellence) would be more likely to be
included. In contrast, consulting the ISPOR Web site to identify
national pharmacoeconomic guidelines can be regarded as a
reproducible and thus systematic method to identify these
guidelines and provide a representative overview of guidance.
In our opinion, there is no better alternative to identify nationalpharmacoeconomic guidelines and consulting the ISPOR Web
site can thus be regarded as the best available method for this
purpose. Furthermore, there will certainly be subjectivity in our
assessment of, for example, what is considered guidance and
what is not. Hence, some of our evaluations may be criticized.
However, by developing a data extraction sheet and organizing
consensus meetings, we put all efforts to keep the assessments
as systematic and objective as possible. Moreover, despite some
potentially subjective judgments, this study aimed to facilitate
informed discussions and advance current practice of
economic evaluations. Finally, our review was restricted to
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effectiveness/benefit assessment might provide recommenda-
tions on handling patient heterogeneity for differences in rela-
tive treatment effectiveness. This restriction is to our opinion
appropriate because economic evaluations have a broader per-
spective; they consider consequences on the absolute scale and
include additional input parameters as baseline risk, health
state utility, and resource utilization. In addition, health eco-
nomic researchers will probably consult and adhere to the
national pharmacoeconomic guideline.
In addition to the limitations in the presented review, current
literature and guidelines might sometimes be confusing concern-
ing the handling of patient heterogeneity. The German guideline
[28] uses patient heterogeneity as an argument for patient-level
simulation (discrete event simulation). This argument is in our
opinion incorrect. Patient-level simulation is not necessarily
required to acknowledge patient heterogeneity (see, e.g., [48,49]).
Subgroups can, for instance, be modeled in cohort models by
letting them start in different health states [50]. Patient-level
simulation is a useful alternative if this becomes too complex [9].
Although it inevitably takes time before new concepts are
incorporated in guidelines, it was obvious that more clear and
specific guidance would be useful. Ideally, guidelines would
clearly state situations in which patient heterogeneity is consid-
ered irrelevant for decision making in their jurisdiction (e.g.,
using equity constraints as the guideline from England & Wales
[25]). This enables researchers to focus on subgroups that are
potentially useful for decision making. The framework presented
by Grutters et al. [9] might be valuable to systematically explore
which sources and inputs of patient heterogeneity are deemed
(ir)relevant. In addition, individual preferences are a special
source of patient heterogeneity. Preference subgroups can be
acknowledged by using individual preferences [5,51]. However, it
has been debated whether individual preferences should be
incorporated in population reimbursement decisions [52–55].
Subgroups based on individual utilities may be inconsistent with
the idea that societal welfare should be determined by aggregat-
ing the preferences of society [56,57]. However, as proposed by
Sculpher and Gafni [58], it is possible to acknowledge diversity in
the preferences of individuals while maintaining the use of utility
values of the general public. Guidelines should clarify how to deal
with differences in individual preferences. The guideline from
England & Wales, for instance, argues against subgroups solely
based on individual utilities (Table 1).
Most guidelines consider patient heterogeneity that is known
at the start of treatment. In addition, the England & Wales
guideline provides guidance to construct treatment continuation
rules based on patient heterogeneity revealed over time [25].
Treatment continuation rules (e.g., based on treatment response)
can be used to adjust treatment plans after treatment start.
However, it might be complex to attain feasible treatment con-
tinuation rules and inform actual reimbursement decisions
based on patient heterogeneity revealed over time. Therefore,
guidelines should clarify, as the England & Wales guideline [25],
how patient heterogeneity revealed over time should be handled.
It is recommended that guidelines be as specific as possible
when stratified analysis should be undertaken (e.g., what justi-
fication is required and in which circumstances post hoc analy-
ses are allowed). This potentially prevents that subgroups are
analyzed only if average cost-effectiveness is hard to show. In
addition, the possibility of false positives due to random noise in
data might caution researchers or policymakers to use subgroups
in their analysis or decision making [9]. These fears, however, are
mainly from an epidemiological perspective [3]. From a health
economic perspective, the statistical significance of subgroups is
irrelevant [59]; rather, its value for reimbursement decisions is
relevant. Certainly, this does not mean that uncertainty isirrelevant [59,60] and data dredging should always be avoided.
The role of stratified analysis in economic evaluations, however,
should in our opinion be considered on the basis of its value for
policy purposes (i.e., the health benefits forgone if subgroups are
neglected), rather than from an epidemiological perspective [61].
The finding that none of the guidelines provided specific
guidance how to select influential subgroups and determine
subgroup thresholds or the optimal number of subgroups for
continuous variables (e.g., to determine age groups) might reflect
that there is no consensus on this topic. Thus, the selection of
patient subgroups, particularly in case multiple (continuous)
variables are considered simultaneously, may require further
methodological research, as currently performed by Saramago
[62] and Espinoza et al. [63] among others. Nevertheless, efforts
have been made in this direction. Willan et al. [61] demonstrated
that regression techniques can be used within the net benefit
framework to explore and select statistically significant patient
characteristics to define subgroups [64]. Furthermore, Basu and
Meltzer [5] proposed a framework to estimate the expected value
of individualized care. By selecting potentially influential varia-
bles based on the parameter-specific value of individualized care,
this framework could be an alternative to the regression techni-
que described above [5,65]. The selected variables can subse-
quently be used in stratified analyses by estimating the benefits
of providing different treatments to different subgroups and
hence calculating the potential value of subgroup policy [1]. This
would give decision makers the opportunity to judge when the
costs of equity constraints are too high [66]. In decision analytic
modeling, stratified analyses can be performed by using different
input values for different subgroups. This can be implemented by
linking input parameters to patient characteristics or by adding
health states and letting different subgroups start out in different
health states [4,6,9,50].
In addition, it might be useful to provide guidance on what
should be presented to support potential reimbursement deci-
sions based on subgroup outcomes. This includes, for instance, to
describe and justify subgroups, provide guidance on specific
tables/figures, and highlight issues as the appropriate use of the
intervention and the feasibility of subgroup policy. These recom-
mendations require a high level of prescription in guidelines,
while many are currently not this directive. It is open to debate
whether decision makers wish to have such prescriptive guide-
lines, or prefer to leave this to the integrity of researchers. In our
opinion, decision makers should clearly state which results are
needed for their appraisal and how these results should be
achieved in the assessment, in order to support uniformity.
Taking into account the differences between jurisdictions (e.g.,
in terms of legislation and normative judgments), it was deemed
impossible to formulate guidance that would be appropriate for
all national pharmacoeconomic guidelines worldwide. Therefore,
we present a checklist in Table 3 to assist national guideline
authorities to formulate comprehensive recommendations with
regards to acknowledging patient heterogeneity in economic
evaluations on the topics identified in this review. Obviously,
researchers are allowed to deviate from guideline recommenda-
tions if appropriately justified. However, especially when consid-
ering a normative subject where subgroups are potentially
included or excluded from treatment reimbursement, guidelines
should in our opinion be specific and directive.
In conclusion, the majority of national pharmacoeconomic
guidelines provide guidance on acknowledging patient hetero-
geneity in economic evaluations. However, because specific
guidance is often lacking, its usefulness is limited. This may
reflect that the importance of acknowledging patient heteroge-
neity is usually recognized while there is a lack of consensus on
specific requirements and methodology to acknowledge and
present patient heterogeneity in economic evaluations. We
Table 3 – Checklist to formulate guidance on
acknowledging patient heterogeneity in economic
evaluation.
Acknowledgment of patient heterogeneity
1 In economic evaluations, patient heterogeneity
& Should not be reflected
& Should be reflected
2 When acknowledging patient heterogeneity, the following inputs
of an economic evaluation should be considered:
& Baseline risk
& Relative treatment effect
& Health state utility
& Resource utilization
3 The following sources of patient heterogeneity should be
considered:
& Demographics
& Preferences
& Clinical characteristics
Methodology to acknowledge patient heterogeneity
4 In order to analyze different sources of patient heterogeneity,
& No justification is required
& This should be justified on the basis of biological plausibility
& This should be justified on the basis of (pre)clinical evidence/
pharmacokinetics
& This should be justified on the basis of statistical plausibility
& This should be justified on the basis of y
5 Subgroups that are a priori not considered relevant for decision
making are those based solely on the following sources of
patient heterogeneity:
& No subgroups are a priori considered irrelevant
& Subgroups based on the following sources are a priori
considered irrelevant: y
6 Patient heterogeneity should be explored on the basis of
& Prespecified subgroups and post hoc analysis should be
avoided
& Prespecified subgroups and post hoc analysis should be used
only to generate hypotheses or to y
& Either post hoc analysis or prespecified subgroups
7 The following methods are suggested to analyze patient
heterogeneity:
& Stratified analysis
& Decision analytic modeling
& Sensitivity or scenario analysis
& Expected value of individualized care
& Regression analysis
& y
8 These methods should be applied in order to
& Incorporate and analyze sources of patient heterogeneity ify
& Incorporate and analyze variability in baseline risk and/or
treatment effect through y
& Determine subgroup thresholds and the number of subgroups
in case of continuous variables through y
& Reflect the precision of subgroup estimates
& Handle patient heterogeneity revealed over time
& y
Presenting patient heterogeneity
9 To support subgroup policymaking, the following information
should be presented:
& Clear definition and justification of subgroups
& Details on data used to produce subgroup estimates
& Details on statistical analyses
& Stratified cost-effectiveness outcomes
& Tornado diagram
& Separate cost-effectiveness acceptability curves
& Implications for distributive aspects/equity
Table 3 – continued
& Validity, reliability, and feasibility of biomarkers of diagnostics
necessary to identify subgroups
& Appropriate use of the intervention
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 8 5 5 – 8 6 2 861advise the further development of national pharmacoeconomic
guidelines to provide specific guidance in each of the categories:
the identification of patient heterogeneity, methods to acknowl-
edge patient heterogeneity, and presenting the results when
acknowledging patient heterogeneity. This could facilitate the
systematic and transparent handling of patient heterogeneity in
economic evaluations worldwide.Acknowledgments
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